Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021)

Historic Current Deferred Revenue for Atea Pharmaceuticals (AVIR) over the last 2 years, with Q3 2021 value amounting to $192.2 million.

  • Atea Pharmaceuticals' Current Deferred Revenue changed N/A to $192.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $192.2 million, marking a year-over-year change of. This contributed to the annual value of $301.4 million for FY2020, which is N/A changed from last year.
  • Per Atea Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $192.2 million for Q3 2021.
  • In the past 5 years, Atea Pharmaceuticals' Current Deferred Revenue ranged from a high of $301.4 million in Q4 2020 and a low of $192.2 million during Q3 2021